This page showcases some of the various clinical trials that we
have been involved with, bringing state of the art technologies and pioneering treatments to the people of New York's Capital District and surrounding region.
We are currently enrolling patients in clinical trials with macular degeneration, diabetic retinopathy, macular edema and several other conditions. Upcoming studies, pending various approvals, will soon be enrolling patients with macular edema, uveitis, ocular inflammation, and other conditions.
 |
INTRAVITREAL
REMICADE
Enrollment: OPEN
2008
|
Macular Degeneration
& Diabetic Retinopathy
This trial involves:
a drug injected into an eye
|
A phase I-pilot study to evaluate
the safety of intravitreal Remicade (Infliximab) Injections for
patients with severe diabetic macular edema or choroidal
neovascularization |
|
|
OPH1000
Enrollment Open
2007-2008 |
Macular Degeneration
This trial involves:
2 drugs injected into an eye |
A phase I study to evaluate
the safety of anti-PDGF Injections in addition to Lucentis |
|
Regeneron |
View 1
Enrollment Open
2007-2008 |
Wet Macular Degeneration
This Trial involves:
a drug injected into an eye |
Phase 3 study to evaluate the VEGF Trap for wet Macular Degeneration
|
|
|
AIN457
Enrollment Open
2007-2008 |
Non-infectious Uveitis
This trial involves:
a drug injected into in the vein |
Phase
2 study to evaluate monoclonal antibodies to IL 17 for uveitis |
 |
AREDS2
Enrollment: OPEN
2006-2011
|
Dry Macular Degeneration
This trial involves:
lutein, zeaxanthin, omega-3 fatty acids |
Prevention of age related macular degeneration and cataracts with vitamin supplementation
Sponsored by the National Institute of Health |
|
SALVAGE
Enrollment Closed
Study Ongoing
2006-2008 |
Macular Degeneration
This trial involves:
a drug injected into an eye |
A phase I/II study to evaluate Scotoma reduction and Limited Visual Acuity in a GE related macular degeneration.
Patients treated with LUCENTIS |
 |
HORIZON
FVF3426
COMPLETED |
Macular Degeneration
This trial involves:
a drug injection into an eye |
Open label extension study with LUCENTIS (rhuFab V2) Therapy for Anchor and Marina patients |
 |
SAILOR
COMPLETED
|
Macular Degeneration
This trial involves:
a drug injected into an eye |
Open label study with LUCENTIS (rhuFab V2> Therapy for Age Related Macular Degeneration |
 |
MARNIA
COMPLETED |
Macular Degeneration
This trial involves:
A drug injected into an eye
A drug injected to an arm vein
laser treatment to the eye
|
Ranibizumab (rhuFab V2) Therapy for patients with Minimally Classic Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration |
 |
ANCHOR
COMPLETED |
Macular Degeneration This Trial involves:
a drug injected into an eye
a drug injected into an arm vein
laser treatment to the eye |
Ranibixumab (rhuFab V2) or Verteporfin (visudyne) Therapy for Patients with Mostly Classical Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration |
 |
PFIZER
COMPLETED |
Macular Degeneration
This trial involves:
a drug injected next to the eye |
Phase I anti-VEGF therapy
Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration
|
 |
EYETECH
COMPLETED
|
Macular Degeneration
This trial involves:
A drug injected into the eye |
Macugen
Compassionate Use for
Patients with Wet Macular Degeneration
|
 |
VIO
COMPLETED
|
Macular Degeneration
This trial involves:
a drug injected into an arm vein
laser treatment to the eye
|
Vereporfin (Visudyne) Therapy for Patients with Entirely Occult Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration
|
|
ADD-V
COMPLETED |
Macular Degeneration
This trial involves:
a drug injected into an arm vein
eye drops |
Vereporfin (Visudyne) and Voltaren drops Therapy for Patients with Subfoveal Choroidal Neovascular Membranes secondary to Macular Degeneration
|
|
INTRAVITREAL
REMICADE
Enrollment: OPEN
2008
|
Macular Degeneration
& Diabetic Retinopathy
This trial involves:
a drug injected into an eye
|
A phase I/pilot study to evaluate
the safety of intravitreal Remicade (Infliximab) Injections |
 |
RISE
FVF4168g
Open |
Diabetic Retinopathy
This Trial Involves:
an oral drug taken daily |
Intravitreal injections of Ranibizumab administered monthly for 24 months for patients with Diabetic Macular Edema |
 |
LILY ARXXANT
B7A-MC-MBCU
Enrollment
Closed
2006-2008 |
Diabetic Retinopathy
This trial involves:
an oral drug taken daily |
Ruboxistaurin for Macular Edema in patients with Diabetes Mellitus
Assesed by Optical Coherence Tomography
|
 |
Completed |
Diabetic Retinopathy
This trial involves:
a drug injected into the eye |
Intravitreal Steroid for diabetic Macular Edema Laser for Diabetic Macular Edema |
|
Completed |
Diabetic Retinopathy
This trial involves:
a drug injected into the eye
|
Modified Grid or Focal Laser for Diabetic Macular Edema |
|
Completed |
Diabetic Retinopathy
This trial involves
A drug injected into the eye |
OCT for Diabetic Macular Edema |
